Kala Azar in South Asia

1. Front Matter

   Pages i-xx

   PDF

2. Introduction Into Kala-Azar

   1. Front Matter

      Pages 1-1

      PDF

   2. Pathology and Mechanism of Disease in Kala-Azar

      • Shyamal Paul, Monira Pervin

      Pages 3-6

   3. Containing Post Kala-Azar Dermal Leishmaniasis (PKDL): Pre-requisite for Sustainable Elimination of Visceral Leishmaniasis (VL) from South Asia

      • Poonam Salotra, Himanshu Kaushal, V. Ramesh

      Pages 7-21

   4. Characteristics of Patients Visiting Suruya Kanta Kala-Azar Research Center in Mymensingh, Bangladesh; Data from a Patient Registry System

      • Masao Iwagami, Bumpei Tojo, Eisei Noiri

      Pages 23-30

3. Therapeutic Strategy to Deal with Emergence of Drug Resistance

   1. Front Matter

      Pages 31-31

      PDF

   2. Epidemiology of Drug-Resistant Kala-Azar in India and Neighboring Countries

      • T. K. Jha

      Pages 33-51

   3. A Therapeutic Strategy for Treating Visceral Leishmaniasis in Regions with Drug Resistance

      • Shyam Sundar, Dipti Agarwal

      Pages 53-66

   4. Treatment of Post-kala-azar Dermal Leishmaniasis

      • V. Ramesh, Prashant Verma

      Pages 67-77

   5. Combination Therapy for Leishmaniases

      • Farrokh Modabber

      Pages 79-88

   6. Vaccine Development for Leishmaniasis

      • Yasuyuki Goto

      Pages 89-99

   7. Siccanin Is a Novel Selective Inhibitor of Trypanosomatid Complex II (Succinate-Ubiquinone Reductase) and a Potent Broad-Spectrum Anti-trypanosomatid Drug Candidate

      • Nozomu Nihashi, Daniel Ken Inaoka, Chiaki Tsuge, Emmanuel Oluwadare Balogun, Yasutaka Osada, Yasuyuki Goto et al.

      Pages 101-122

4. Diagnostic Strategy Enhancing Kala-Azar Elimination Program

   1. Front Matter

      Pages 123-123

      PDF

   2. Challenges in the Diagnosis of Visceral Leishmaniasis on the Indian Subcontinent

      • Suman Rijal, François Chappuis, Jorge Alvar, Marleen Boelaert

      Pages 125-134

   3. Changes of Leishmania Antigens in Kala-Azar Patients’ Urine After Treatment

      • Sharmina Deloer, Sohel Mohammad Samad, Hidekazu Takagi, Chatanun Eamudomkarn, Kazi M. Jamil, Eisei Noiri et al.

      Pages 135-140

   4. Potentiality of Urinary L-FABP Tests to Kala-Azar Disease Management

      • Eisei Noiri, Yoshifumi Hamasaki, Bumpei Tojo, Kazi M. Jamil, Kent Doi, Takeshi Sugaya

      Pages 141-160

   5. Antibody Capture Direct Agglutination Test (abcDAT) for Diagnosis of Visceral Leishmaniasis with Urine

      • Fumiaki Nagaoka, Hidekazu Takagi, Eisei Noiri, Makoto Itoh

      Pages 161-165

   6. Loop-Mediated Isothermal Amplification ( LAMP ): Molecular Diagnosis for the Field Survey of Visceral Leishmaniasis

      • Hidekazu Takagi, Makoto Itoh, Eisei Noiri

      Pages 167-171

   7. Applicability of Multiplex Real-Time PCR to Visceral Leishmaniasis

      • Yoshifumi Hamasaki, Hirofumi Aruga, Chizu Sanjoba, Hidekazu Takagi, Shyamal Paul, Yoshitsugu Matsumoto et al.

      Pages 173-183

5. Pathogenesis of Kala-Azar and PKDL

   1. Front Matter

      Pages 185-185

      PDF

Visceral leishmaniasis (VL), (also known as black fever or Kala-azar) is a life-threatening disease first reported from the Indian subcontinent. VL ranks as the world’s second largest parasitic disease killer and is a neglected tropical disease. Most of those infected by this life-threatening disease are uneducated daily wagers working to support their families, and vectors easily disseminate the disease to their neighbors. Owing to recent involvement of stakeholders, the number of patients is decreasing, but eradication remains a distant goal.

This second edition presents latest reports of visceral Leishmaniasis by specialists working at the forefront of the endemic areas in Indian subcontinent. It also introduces vaccine development and inhibitors to Trypanosomatidae; some of them describing feasibility studies in visceral Leishmaniasis for the first time.

Recent progress of the Science and Technology Research Partnership for Sustainable Development (SATREPS) is also reviewed and the contents share this collaborative research from the forefront of endemic sites in Bangladesh.

Widely covering basic, clinical, epidemiological and entomological aspects, this volume will be of great interest to dedicated researchers interested inLeishmaniasis and to experts of NTDs in global health.

 

There is a tide in the affairs of men. Which, taken at the flood, leads on to fortune; Omitted, all the voyage of disease control is bound in shallows and in miseries.

~modified from Shakespeare ~

• Neglected Tropical Diseases
• succinate-coenzyme Q reductase
• multiplex PCR
• urine
• Geographic Information System
• vector control
• antibacterial drug resistance

• The University of Tokyo Hospital, Bunkyō, Tokyo, Japan

  E. Noiri

• Kalazar Research Center, Muzaffarpur, India

  T.K. Jha

Eisei NOIRI, M.D., Ph.D. is the JICA Chief Advisor of Japanese ODA project named SATREPS and the JST primary investigator of SATREPS. The project is the first and largest NTDs mission targeting to Indian subcontinent, especially to Bangladesh. The research at the frontier of endemic area is conducted from the experiences on the life science basic scientific research including molecular biology, genetics, and physiology. In addition, epidemiological surveillance and urine combined GIS analysis are highly esteemed because of the capabilities to elucidate exact foci at the endemic area.

Dr. Jha’s original research studies have been published in journals like the New England Journal of Medicine, the British Medical Journal, Transactions of the Royal Society of Tropical Medicine, the American Journal of Tropical Medicine and the Journal of American Society of Tropical Medicine and Hygiene. 

Policies and ethics